A positive EFSA opinion can sound like a green light for CBD. This one is narrower: it assesses a single ingredient for a specific food supplement. It does not grant EU authorisation for CBD products.
What EFSA viewed positively
In September 2026, EFSA’s Panel on Nutrition, Novel Foods and Food Allergens assessed cannabidiol made by chemical synthesis. It must be at least 98% pure and is intended to be sold only dissolved in MCT oil as a food supplement. The proposed maximum is 2 mg a day. The target group is adults over 25. The product is not intended for pregnant or breastfeeding women. EFSA could not establish safety for people taking medication.
The Panel concluded that the ingredient is safe under those proposed conditions. Its assessment included a 90 day study in rats, in which the liver was the key target organ. Because data are still missing, including on reproductive and developmental toxicity, EFSA applied an uncertainty factor of 400. This is not general advice to take CBD.
Why the 2 mg figure does not apply to every CBD product
In February 2026, EFSA had already set a provisional safe intake level of about 2 mg of CBD a day for a 70 kg adult. That figure also reflects substantial data gaps and sits within the assessment of CBD as a novel food. It is not a blanket approval or a dosage instruction for CBD oils sold in shops.
